OSE Immunotherapeutics SA (LON: 0RAD)

Market Cap	118.76M
Revenue (ttm)	70.74M
Net Income (ttm)	39.03M
Shares Out	n/a
EPS (ttm)	1.71
PE Ratio	3.04
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	186
Average Volume	104
Open	6.56
Previous Close	6.47
Day's Range	6.56 - 6.56
52-Week Range	2.69 - 9.30
Beta	0.96
RSI	34.33
Earnings Date	Jan 1, 2025

About OSE Immunotherapeutics

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 55
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RAD

Financial Performance

In 2023, OSE Immunotherapeutics's revenue was 2.23 million, a decrease of -87.83% compared to the previous year's 18.30 million. Losses were -23.00 million, 29.5% more than in 2022.

Financial numbers in EUR